

*This report contains the collective views of an international group of experts and
does not necessarily represent the decisions or the stated policy of the World Health Organization*

WHO Technical Report Series

885

WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS

Thirty-fifth Report



World Health Organization

Geneva 1999

WHO Library Cataloguing in Publication Data

WHO Expert Committee on Specifications for Pharmaceutical Preparations (1997: Geneva, Switzerland)
WHO Expert Committee on Specifications for Pharmaceutical Preparations : thirty-fifth report.

(WHO technical report series : 885)

1. Pharmaceutical preparations — standards 2. Drug industry 3. Quality control
4. Reference standards 5. Legislation, Drug 6. Guidelines 1. Title II. Series

ISBN 92 4 120885 6
ISSN 0512-3054

(Classification NLM: QV 771)

The World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. Applications and enquiries should be addressed to the Office of Publications, World Health Organization, Geneva, Switzerland, which will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available.

© World Health Organization 1999

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

**Typeset in Hong Kong
Printed in Spain**

98/12121 — Best-set/Fotojoe — 6500

Contents

1. Introduction	1
2. <i>The international pharmacopoeia and related issues</i>	2
2.1 Quality specifications for drug substances and dosage forms	2
2.2 Simple test methodology	3
3. International Chemical Reference Substances and Infrared Reference Spectra	4
3.1 Establishment of International Chemical Reference Substances	4
3.2 International Infrared Reference Spectra	5
3.3 Use of International Chemical Reference Substances and Infrared Reference Spectra	5
3.4 Guidelines for the establishment, maintenance and distribution of chemical reference substances	5
4. Quality control — national laboratories	6
4.1 Good laboratory practices in government drug quality control laboratories	6
4.2 Information on external quality assessment	6
5. Good manufacturing practices	6
5.1 Adoption of additional guidelines	6
5.2 Good manufacturing practices for sterile products	7
5.3 Relationship between pharmacopoeial requirements and manufacturers' internal specifications	7
6. Quality systems and inspection	7
6.1 Quality systems for GMP inspectorates	7
6.2 Pre-approval inspection	7
6.3 Guidelines for inspection of drug distribution channels	8
6.4 Use of simple test methods by inspectors	8
7. Other quality assurance topics	8
7.1 Compendia	8
7.2 Packaging for pharmaceutical products	8
7.3 Multisource pharmaceutical products	8
7.4 Guidelines for good pharmacy practice	9
8. Nomenclature and terminology	9
8.1 International Nonproprietary Names for pharmaceutical substances	9
8.2 Terminology	9
9. Legal aspects of pharmaceuticals	10
9.1 Drug regulatory legislation	10
9.2 National implementation guidelines for combating counterfeit pharmaceuticals	10
10. Regulatory issues	11
10.1 WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce	11

10.1.1	Finished pharmaceutical products	11
10.1.2	Active pharmaceutical ingredients	11
10.2	WHO model system for computer-assisted drug registration	11
10.3	Model guidelines for the international provision of controlled medicines for emergency medical care	12
11.	Training activities	12
11.1	Training programmes for drug regulators and related activities	12
11.2	Training programmes for the detection of counterfeit pharmaceutical products	13
12.	Pharmaceuticals contaminated with diethylene glycol	13
	Acknowledgements	13
	References	17
	Annex 1	
	List of available International Chemical Reference Substances	20
	Annex 2	
	List of available International Infrared Reference Spectra	27
	Annex 3	
	General guidelines for the establishment, maintenance and distribution of chemical reference substances	29
	Annex 4	
	Good manufacturing practices: authorized person — role, functions and training	45
	Annex 5	
	Good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients	50
	Annex 6	
	Guidelines for inspection of drug distribution channels	72
	Annex 7	
	Good pharmacy practice in community and hospital pharmacy settings	93
	Annex 8	
	National drug regulatory legislation: guiding principles for small drug regulatory authorities	102
	Annex 9	
	Provisional guidelines for developing training programmes: inspection and examination of counterfeit pharmaceuticals	143

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Geneva, 21–25 April 1997

Members

Professor I. Addae-Mensah, Chancellor, University of Ghana, Legon, Ghana
(*Rapporteur*)

Professor A.A. Haggag, Vice-Dean, Faculty of Pharmacy, University of Tanta, Tanta, Egypt

Dr M.K. Majumdar, Director, Central Drugs Laboratory, WHO Collaborating Centre for Quality Assurance of Essential Drugs, Calcutta, India

Professor T.L. Paál, Director-General, National Institute of Pharmacy, WHO Collaborating Centre for Drug Information and Quality Assurance, Budapest, Hungary

Miss M.L. Rabouhans, Scientific Editor-in-Chief, British Pharmacopoeia Commission, London, England (*Chairperson*)

Dr Y. Takeda, Senior Managing Director, Society of Japanese Pharmacopoeia, Tokyo, Japan

Dr R.L. Williams, Deputy Director, Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA

Professor Yang Zhong-Yuan, Director, Guangzhou Municipal Institute for Drug Control, Guangzhou, China (*Vice-Chairperson*)

Representatives of other organizations*

Commonwealth Pharmaceutical Association (CPA) and International Pharmaceutical Federation (FIP)

Professor H.H. Blume, Head, Central Laboratory of German Pharmacists, Eschborn, Germany

International Federation of Pharmaceutical Manufacturers Associations (IFPMA)

Miss M. Cone, Vice-President for Scientific Affairs, Geneva, Switzerland

Dr O. Morin Carpentier, Manager, Pharmaceutical and Biological Affairs, Geneva, Switzerland

World Federation of Proprietary Medicine Manufacturers (WFPMM)

Dr J.A. Reinstein, Director-General, London, England

Secretariat

Mr J.A. Halperin, Executive Vice President and Chief Executive Officer, United States Pharmacopeia, Rockville, MD, USA (*Temporary Adviser*)

* Unable to attend: European Commission (EC), Brussels, Belgium; Pharmaceutical Inspection Convention (PIC), Geneva, Switzerland; United Nations Industrial Development Organization (UNIDO), Vienna, Austria; United Nations International Drug Control Programme (UNDCP), Vienna, Austria.

Dr J. Idänpään-Heikkilä, Director, Division of Drug Management and Policies, WHO, Geneva, Switzerland (*Secretary*)

Dr S. Kopp-Kubel, Responsible Officer (a.i.), Quality Assurance, Division of Drug Management and Policies, WHO, Geneva, Switzerland

Professor H.G. Kristensen, Department of Pharmaceutics, The Royal Danish School of Pharmacy, Copenhagen, Denmark (*Temporary Adviser*)

Dr T.P. Layloff, Director, Division of Testing and Applied Analytical Development, Food and Drug Administration, St Louis, MO, USA (*Temporary Adviser*)

Dr A.P. Mechkovski, Moscow, Russian Federation (*Consultant*)

Dr J.H.M^cB. Miller, Head of Division III (Laboratory), European Department for the Quality of Medicines, Council of Europe, Strasbourg, France (*Temporary Adviser*)

Mr M.G. Moester, Senior Inspector of Health Care, Department of Health, Rijswijk, Netherlands (*Temporary Adviser*)

Ms M. Schmid, Technical Officer, Quality Assurance, Division of Drug Management and Policies, WHO, Geneva, Switzerland

Ms A. Wehrli, Chief, Regulatory Support, Division of Drug Management and Policies, WHO, Geneva, Switzerland

Mrs M. Westermarck, Director, WHO Collaborating Centre for Chemical Reference Substances, Apoteksbolaget AB, National Corporation of Swedish Pharmacies, Central Laboratory, Stockholm, Sweden (*Temporary Adviser*)

1. Introduction

The WHO Expert Committee on Specifications for Pharmaceutical Preparations met in Geneva from 21 to 25 April 1997. The Director-General of WHO, Dr Hiroshi Nakajima, in his keynote address to open the meeting, stressed the need for continued international support to developing countries for ensuring drug quality. In a rapidly changing world, the globalization of economic forces, the expansion of travel and trade, and the trend towards privatization, together with new technologies, changing life-styles, and demographic shifts, had immediate implications for public health. In response, WHO had been engaged since 1995 in a revision of its health-for-all strategy. The goal of health for all in the 21st century presented WHO and its partners with an unprecedented challenge. It would be of the utmost importance for WHO to maintain its normative role if it was to meet the needs and expectations of its Member States. In addition, WHO would have to concentrate its resources on targeted areas of health work: essential drugs, for example, were recognized as having a high priority. Developing countries, in particular, would need international support in assuring drug and vaccine quality. WHO's normative activities had become increasingly important to its Member States as they strived towards regional and global harmonization of standards for production, quality control, safety, certification, and trade in pharmaceuticals and biologicals. WHO guidelines and publications were thus a valuable resource for countries establishing and strengthening their own regulatory systems. The goal of the Expert Committee was to maximize the value and availability of these resources. There was an increased need for the exchange of information and for harmonization at an international level, and for the appropriate use of available technical expertise within countries.

At the World Health Assembly in 1996, concern had been expressed about persistent problems in ensuring the quality of medicines. The Assembly had urged Member States to support mechanisms for monitoring and controlling the efficacy, quality and safety of drugs. In particular, the growing incidence of production, distribution and sale of counterfeit, spurious or substandard pharmaceutical products in developed and developing countries was a matter of concern for WHO. The Assembly had also called on WHO in resolution WHA49.14 "to continue the development, harmonization and promotion of standards to enhance drug regulatory and quality control mechanisms" and "to promote vigorously the use of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce".

The Director-General informed the participants that quality assurance had been extensively discussed at the Eighth International Conference of Drug Regulatory Authorities held in November 1996 in Manama, Bahrain. Those discussions showed clearly that WHO normative guidelines were appreciated throughout the world. The Conference had also reviewed progress made in the international harmonization of regulatory requirements, and collaboration between WHO and the International Conference on Harmonisation (ICH). WHO had participated as an observer since the establishment of the ICH process in 1990. WHO's objective in doing so was to provide a bridge between the 17 countries actively involved in the ICH process and the rest of WHO's Member States. As the World Health Assembly had asserted in May 1992 in resolution WHA45.28, WHO's role was to ensure that harmonization benefited all concerned.

2. ***The international pharmacopoeia* and related issues**

2.1 **Quality specifications for drug substances and dosage forms**

The Committee received a report of a worldwide survey on the use of *The international pharmacopoeia*, and noted with satisfaction its widespread use in virtually all areas of the world. The report clearly indicated that *The international pharmacopoeia* plays a major role in defining the specifications of pharmaceutical products. It also provides a valuable tool in the quality assurance of imported products. It was suggested that manufacturers in exporting countries should be encouraged to include an indication of compliance with *The international pharmacopoeia*, wherever appropriate, in the product information, to make it easier for developing countries to check the quality of imported products.

The Committee was informed that Volume 5 of *The international pharmacopoeia* would shortly be submitted for publication. Monographs for Volume 6 were in preparation. In cases where there was insufficient information from official sources, the monographs would be prepared with the assistance of pharmaceutical manufacturers.

Texts on general methods to be included in *The international pharmacopoeia* were approved for bacterial endotoxins, the visual inspection of particulate matter and extractable volume for parenteral prepara-

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30533

